Candidate

Target

Disease

Pre-clinical

Phase I

Phase II (POC)

Pivotal

INKmune

NK Cells

Relapsed/refractory ovarian cancer

*High risk MDS

INB03

MDSC

CPI resistance

*Trastuzumab resistance

XPro1595

Microglia

Alzheimer’s Disease

 

* Potential future programs

Have a Question?
858 964 3720
Email Us
dmoss@inmunebio.com
Opening Hours
M - F 8am to 5pm PST